Trial Profile
Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Mannitol
- Indications Arteriovenous malformations; Meningioma; Necrosis; Neurilemmoma; Trigeminal neuralgia
- Focus Therapeutic Use
- Acronyms LIBERTI
- Sponsors Norton Healthcare Limited
- 01 Dec 2022 Results assessing the safety and efficacy of a single low-dose targeted bevacizumab infusion after blood-brain barrier disruption (BBBD) in adult patients with steroid-refractory brain radiation necrosis, published in the Journal of Neurosurgery.
- 25 Jun 2021 Status changed from active, no longer recruiting to completed.
- 09 Oct 2017 Planned number of patients changed from 15 to 10.